US Pharma MarketingMicrobiome startup raises $48M for immunotherapy and malnutrition treatments
A biotech startup has studied a cancer survivor’s stool and identified about 50 strains of bacteria that collectively seemed to create the right conditions to help immunotherapy cure her advanced colorectal cancer. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals…
Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop.
A biotech startup has studied the woman’s stool and ...
Source: Endpoints News